The Journey to Serve Over 1 Million Cancer Patients with Oncotype DX Tests
Physicians used Oncotype DX
Cancer Patient Outcomes Improved
Over 1 Million
Patients Tested with the Oncotype DX Test Avoiding Over-and Under-Treatment for the Breast, Prostate and Colon Cancer
Making Cancer Care Smarter
As the world's leading provider of genomic-based diagnostic tests, we're committed to making cancer care smarter with our Oncotype IQ Genomic Intelligence Platform. This expanding suite of tissue- and liquid-based tests answers specific questions across the patient journey—from diagnosis through treatment and ongoing cancer management-through a single, trusted source easily accessed via our secure web-based platform for physicians to interpret and share results with patients.
Oncotype IQ Genomic Intelligence Platform answers questions across the patient journey
Do I have an aggressive disease?
Do I need radiation?
Do I need surgery?
Do I need chemo?
What stage is my cancer?
What targeted therapies could benefit me?
"With millions of cancer patients around the world, it is critical to be able to individualize care. Oncotype DX tests have paved the way for precision medicine by providing personalized information based on the unique biology of every cancer, and by enabling confident, individualized treatment decisions. Genomic testing has become a mainstream component of cancer care, and patients are seeing the benefits through improved outcomes," said Harold A. Burstein, M.D., Ph.D., medical oncologist at the Dana-Farber Cancer Institute.
The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions, helping to guide treatment decisions for more than 1 million cancer patients worldwide. The company's flagship product, the Oncotype DX Breast Recurrence Score test, is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
Launched recently, in collaboration with Epic Sciences, the Oncotype DX AR-V7 Nucleus Detect assay helps men with metastatic prostate cancer determine the most effective, life-sustaining therapy. Performed in Epic Science's CLIA-certified laboratory, the test detects the expression of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells.
The portfolio of Oncotype DX tests is supported by a significant amount of clinical evidence, including 125 clinical studies involving 140,000 patients and more than 150 journal publications. Recently, the landmark TAILORx trial was published. This trial used the Oncotype DX Breast Recurrence Score test to define, with precision, the individual benefit of chemotherapy for early-stage breast cancer patients.
New to the Oncotype IQ portfolio is the Oncotype MAP Pan-Cancer Tissue test, a rapid comprehensive genomic profiling panel that aids therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer by identifying actionable genomic alterations within 3-5 business days* †.
Our Genomic Tests
The only genomic test proven to predict a patient’s individual benefit from chemotherapy.
For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.
The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ.
For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.
Decide whether immediate treatment is necessary or confidently opt for active surveillance.
For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology (low-grade [3+3, 3+4], organ-confined disease).
The first and only test to identify patients who will not respond to AR-targeted therapies
For patients with metastatic castration resistant prostate cancer, the Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen receptor (AR) therapies such as abiraterone and enzalutamide.
A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures.
For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment.
A rapid, comprehensive genomic profiling panel to aid therapy selection for a breadth of solid tumor types.
For patients with advanced, metastatic, refractory, or recurrent cancer, the Oncotype MAP Pan-Cancer Tissue test provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient’s tumor profile and effectively recommend targeted therapies or clinical trials.
Oncotype IQ Platform Evolution
The Road Ahead
Looking ahead, we will continue to expand our Oncotype IQ platform through internal development programs and strategic partnerships, all with the goal of making cancer care smarter.